What is the recommended duration of therapy with Eliquis (apixaban) for indications such as non‑valvular atrial fibrillation, acute deep‑vein thrombosis or pulmonary embolism, and postoperative thromboprophylaxis after hip or knee replacement?

Duration of Apixaban (Eliquis) Therapy by Indication

For non-valvular atrial fibrillation, apixaban is continued indefinitely; for acute DVT/PE, treat with 10 mg twice daily for 7 days then 5 mg twice daily for at least 6 months (with option for reduced-dose extended therapy); for hip replacement thromboprophylaxis, use 2.5 mg twice daily for 32–38 days, and for knee replacement, use 2.5 mg twice daily for 10–14 days. 1

Non-Valvular Atrial Fibrillation

Apixaban should be continued indefinitely for stroke prevention in patients with non-valvular atrial fibrillation, as the thromboembolic risk persists as long as the arrhythmia is present. 1

• The standard dose is 5 mg orally twice daily for most patients 1
• Use the reduced dose of 2.5 mg twice daily if the patient meets ≥2 of the following criteria: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL (133 μmol/L) 2
• Annual reassessment of the risks and benefits of continuing anticoagulation is recommended, though discontinuation is rarely appropriate unless bleeding risk becomes prohibitive 3

Acute Deep Vein Thrombosis and Pulmonary Embolism

Initial Treatment Phase

Start with apixaban 10 mg orally twice daily for the first 7 days, then reduce to 5 mg twice daily for the remainder of therapy. 3, 1

Minimum Treatment Duration

• At least 3 months of anticoagulation is required for provoked VTE (associated with transient risk factors such as surgery, trauma, or immobility) 3
• At least 6 months is recommended for unprovoked VTE or VTE with persistent risk factors 3, 4

Extended/Indefinite Therapy Decision

After completing the initial 6-month treatment course, consider extended anticoagulation based on:

• Unprovoked VTE: Continue indefinitely with either standard-dose (5 mg twice daily) or reduced-dose (2.5 mg twice daily) apixaban 4
• Provoked VTE with enduring risk factors (e.g., active cancer, thrombophilia, obesity, chronic immobility): Extended therapy with reduced-dose apixaban (2.5 mg twice daily) reduces recurrent VTE by 87% compared to placebo (1.3% vs 10.0%, HR 0.13) 5
• Cancer-associated VTE: Extended reduced-dose apixaban (2.5 mg twice daily) is noninferior to full-dose for preventing recurrence and causes less bleeding (12.1% vs 15.6%, HR 0.75) 6

The choice between standard-dose (5 mg twice daily) and reduced-dose (2.5 mg twice daily) for extended therapy is conditional, as both regimens show similar efficacy for preventing recurrent VTE with comparable bleeding rates. 4

Postoperative Thromboprophylaxis After Hip Replacement

Apixaban 2.5 mg orally twice daily for 32–38 days (approximately 5 weeks) starting 12–24 hours after wound closure. 2, 7, 1

• This extended duration is superior to standard 10–14 day enoxaparin prophylaxis, reducing total VTE/death from 3.9% to 1.4% (RR 0.36) 8
• Do not start apixaban preoperatively; the first dose should be given 12–24 hours post-surgery to minimize bleeding risk 7, 1

Postoperative Thromboprophylaxis After Knee Replacement

Apixaban 2.5 mg orally twice daily for 10–14 days (approximately 2 weeks) starting 12–24 hours after wound closure. 2, 7, 1

• In the ADVANCE-2 trial, this regimen reduced total VTE/death from 24.4% to 15.1% (RR 0.62) compared to enoxaparin 40 mg daily 9
• The ADVANCE-1 trial (comparing to enoxaparin 30 mg twice daily) did not meet noninferiority criteria, though bleeding was lower with apixaban 10

Perioperative Management: Interruption Before Surgery

When elective surgery or invasive procedures require temporary discontinuation:

Low-to-Moderate Bleeding Risk Procedures

Stop apixaban 1 day before the procedure (skip 2 doses, allowing approximately 24 hours for drug clearance). 11, 12, 13

High Bleeding Risk Procedures

Stop apixaban 2 days before the procedure (skip 4 doses, allowing approximately 48 hours for drug clearance). 11, 12, 2, 13

Neuraxial Anesthesia

Stop apixaban for at least 2–3 days (48–72 hours) before spinal or epidural anesthesia to avoid catastrophic epidural hematoma. 11, 2, 13

Minimal Bleeding Risk Procedures

Continue apixaban without interruption for dental extractions, cataract surgery, pacemaker implantation, and minor dermatologic procedures. 13, 14

• For dental extractions specifically, use tranexamic acid mouthwash (10 mL of 5% solution) immediately before and 2–3 times daily for 1–2 days post-procedure for additional hemostatic support 14

Perioperative Management: Resumption After Surgery

Low Bleeding Risk Surgery

Resume apixaban 24 hours postoperatively at the full therapeutic dose (5 mg twice daily for VTE/AF, or 2.5 mg twice daily for orthopedic prophylaxis). 11, 12, 2

High Bleeding Risk Surgery

Resume apixaban 48–72 hours postoperatively once surgical hemostasis is confirmed, starting at the full therapeutic dose. 11, 12, 2

Bridging Therapy

Bridging with heparin is not recommended when interrupting apixaban for surgery, as the rapid offset (half-life 8–14 hours) and rapid onset of action obviate the need for interim anticoagulation. 2, 13

• The only exception is patients at very high thrombotic risk (e.g., mechanical heart valve, stroke/TIA within 3 months, CHADS₂ score ≥5), though apixaban is contraindicated in mechanical valve patients 11, 2

Common Pitfalls and Caveats

• Renal function monitoring: Apixaban is 27% renally eliminated; avoid in severe renal impairment (CrCl <15 mL/min) and use reduced dosing when CrCl 15–29 mL/min combined with other dose-reduction criteria 15, 2
• Drug interactions: Avoid concomitant use with strong dual inhibitors of CYP3A4 and P-glycoprotein (e.g., ketoconazole, ritonavir) as they significantly increase apixaban levels 7
• Switching from warfarin: When transitioning from warfarin to apixaban, start apixaban when INR <2.0; when switching from apixaban to warfarin, co-administer for 2 days until INR reaches therapeutic range 1
• Early phase of acute VTE: If surgery is needed during the first 3 weeks of DVT/PE treatment (when higher apixaban doses are used), a multidisciplinary discussion is required as standard perioperative protocols may not apply 2